These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 24430787)

  • 21. Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial.
    Gerstein HC; Ratner RE; Cannon CP; Serruys PW; García-García HM; van Es GA; Kolatkar NS; Kravitz BG; Miller DM; Huang C; Fitzgerald PJ; Nesto RW;
    Circulation; 2010 Mar; 121(10):1176-87. PubMed ID: 20194881
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients.
    Marre M; Van Gaal L; Usadel KH; Ball M; Whatmough I; Guitard C
    Diabetes Obes Metab; 2002 May; 4(3):177-86. PubMed ID: 12047396
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nateglinide reduces carotid intima-media thickening in type 2 diabetic patients under good glycemic control.
    Mita T; Watada H; Shimizu T; Tamura Y; Sato F; Watanabe T; Choi JB; Hirose T; Tanaka Y; Kawamori R
    Arterioscler Thromb Vasc Biol; 2007 Nov; 27(11):2456-62. PubMed ID: 17872451
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pioglitazone decreases coronary artery inflammation in impaired glucose tolerance and diabetes mellitus: evaluation by FDG-PET/CT imaging.
    Nitta Y; Tahara N; Tahara A; Honda A; Kodama N; Mizoguchi M; Kaida H; Ishibashi M; Hayabuchi N; Ikeda H; Yamagishi S; Imaizumi T
    JACC Cardiovasc Imaging; 2013 Nov; 6(11):1172-82. PubMed ID: 24229770
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [A compensated type 2 diabetic patient? Fasting blood glucose can be deceptive].
    MMW Fortschr Med; 2004 Feb; 146(7):62. PubMed ID: 15347061
    [No Abstract]   [Full Text] [Related]  

  • 26. Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials.
    Krum H; McMurray JJ; Horton E; Gerlock T; Holzhauer B; Zuurman L; Haffner SM; Bethel MA; Holman RR; Califf RM
    Cardiovasc Ther; 2010 Apr; 28(2):124-32. PubMed ID: 20184589
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improvement of glycaemic control by nateglinide decreases systolic blood pressure in drug-naive patients with type 2 diabetes.
    González-Clemente JM;
    Eur J Clin Invest; 2008 Mar; 38(3):174-9. PubMed ID: 18257780
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes.
    Hollander PA; Schwartz SL; Gatlin MR; Haas SJ; Zheng H; Foley JE; Dunning BE
    Diabetes Care; 2001 Jun; 24(6):983-8. PubMed ID: 11375357
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glycaemic status influences the nature and severity of coronary artery disease.
    Berry C; Noble S; Grégoire JC; Ibrahim R; Levesquie S; Lavoie MA; L'Allier PL; Tardif JC
    Diabetologia; 2010 Apr; 53(4):652-8. PubMed ID: 20225394
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of combined lipid lowering with blood pressure control on coronary plaque regression: rationale and design of MILLION study.
    Kawashiri MA; Sakata K; Gamou T; Kanaya H; Miwa K; Ueda K; Higashikata T; Mizuno S; Michishita I; Namura M; Nitta Y; Katsuda S; Okeie K; Hirase H; Tada H; Uchiyama K; Konno T; Hayashi K; Ino H; Nagase K; Terashima M; Yamagishi M
    Heart Vessels; 2015 Sep; 30(5):580-6. PubMed ID: 24895097
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized dose ranging study of the reduction of fasting and postprandial glucose in type 2 diabetes by nateglinide (A-4166).
    Gribble FM; Manley SE; Levy JC
    Diabetes Care; 2001 Jul; 24(7):1221-5. PubMed ID: 11423506
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia.
    Saloranta C; Hershon K; Ball M; Dickinson S; Holmes D
    J Clin Endocrinol Metab; 2002 Sep; 87(9):4171-6. PubMed ID: 12213867
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of baseline lipoprotein and C-reactive protein levels on coronary atheroma regression following high-intensity statin therapy.
    Puri R; Nissen SE; Shao M; Uno K; Kataoka Y; Kapadia SR; Tuzcu EM; Nicholls SJ
    Am J Cardiol; 2014 Nov; 114(10):1465-72. PubMed ID: 25282317
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Nateglinide].
    Notoya Y; Kikuchi M
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():371-5. PubMed ID: 12387020
    [No Abstract]   [Full Text] [Related]  

  • 35. Efficacy and safety of mitiglinide versus nateglinide in newly diagnose patients with type 2 diabetes mellitus: a randomized double blind trial.
    Li L; Yang M; Li Z; Yan X; Guo H; Pan H; Liu H; Liao Y; Yang G
    Diabetes Obes Metab; 2012 Feb; 14(2):187-9. PubMed ID: 21895920
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship between glycemic control and coronary artery disease severity, prevalence and plaque characteristics by computed tomography coronary angiography in asymptomatic type 2 diabetic patients.
    Tavares CA; Rassi CH; Fahel MG; Wajchenberg BL; Rochitte CE; Lerario AC
    Int J Cardiovasc Imaging; 2016 Oct; 32(10):1577-85. PubMed ID: 27432440
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intensive glucose lowering in cardiovascular risk management - unsolved questions - .
    Shimabukuro M; Masuzaki H; Sata M
    Circ J; 2012; 76(3):593-5. PubMed ID: 22293455
    [No Abstract]   [Full Text] [Related]  

  • 38. Treatment of patients over 64 years of age with type 2 diabetes: experience from nateglinide pooled database retrospective analysis.
    Del Prato S; Heine RJ; Keilson L; Guitard C; Shen SG; Emmons RP
    Diabetes Care; 2003 Jul; 26(7):2075-80. PubMed ID: 12832316
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased risk of cardiovascular mortality by strict glycemic control (pre-procedural HbA1c < 6.5%) in Japanese medically-treated diabetic patients following percutaneous coronary intervention: a 10-year follow-up study.
    Funamizu T; Iwata H; Nishida Y; Miyosawa K; Doi S; Chikata Y; Shitara J; Endo H; Wada H; Naito R; Ogita M; Dohi T; Kasai T; Okazaki S; Isoda K; Miyauchi K; Daida H
    Cardiovasc Diabetol; 2020 Feb; 19(1):21. PubMed ID: 32070335
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Coronary microvascular dysfunction is associated with poor glycemic control amongst female diabetics with chest pain and non-obstructive coronary artery disease.
    Sara JD; Taher R; Kolluri N; Vella A; Lerman LO; Lerman A
    Cardiovasc Diabetol; 2019 Feb; 18(1):22. PubMed ID: 30819191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.